Summary
General Electric Company (GE) announced a significant divestiture through an equity and asset purchase agreement with Danaher Corporation, filed on February 25, 2019. GE will sell its BioPharma business, a part of its Healthcare segment's Life Sciences division, to Danaher for approximately $21.4 billion, subject to adjustments. This transaction is a key step in GE's broader strategy to streamline its operations and manage its financial structure. The sale is expected to be completed by the fourth quarter of 2019, pending regulatory approvals and other standard closing conditions. This divestiture represents a substantial capital inflow for GE, which it can likely use to further reduce its debt load and improve its financial flexibility. Investors should monitor the progress of this sale and GE's subsequent use of the proceeds. The company has also indicated ongoing plans to exit equity ownership positions in Baker Hughes, a GE company (BHGE) and Wabtec, signaling a continued focus on portfolio optimization and deleveraging.
Key Highlights
- 1GE to sell its BioPharma business (part of GE Healthcare's Life Sciences) to Danaher Corporation for approximately $21.4 billion.
- 2The transaction is an equity and asset purchase, with Danaher acquiring specific assets and subsidiaries related to the BioPharma business.
- 3The deal is subject to customary closing conditions, including regulatory approvals.
- 4Expected closing date for the transaction is the fourth quarter of 2019.
- 5This divestiture is a material step in GE's strategic plan to simplify its structure and manage its financial obligations.
- 6Proceeds from the sale are expected to aid in deleveraging and improving GE's financial position.
- 7GE also reiterates plans to exit its equity stakes in Baker Hughes (BHGE) and Wabtec.